Results 31 to 40 of about 1,107,201 (376)
Cancers, 2020 Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality.
R. Vaddepally +4 more
semanticscholar +1 more source
European Journal of Health Economics, 2023 Over the past decades, US Congress enabled the US Food and Drug Administration (FDA) to facilitate and expedite drug development for serious conditions filling unmet medical needs with five special designations and review pathways: orphan, fast track ...
D. Michaeli +4 more
semanticscholar +1 more source
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
Theranostics, 2022 Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease.
Yue Huang +3 more
semanticscholar +1 more source
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Nature Immunology, 2020 Cytosolic sensing of pathogens and damage by myeloid and barrier epithelial cells assembles large complexes called inflammasomes, which activate inflammatory caspases to process cytokines (IL-1β) and gasdermin D (GSDMD).
J. Hu +17 more
semanticscholar +1 more source
A review of new drugs approved by the food and drug administration in 2022
Journal of Family Medicine and Primary Care, 2023 Introduction: The drugs approved by the Food and Drug Administration (FDA) in 2022, for the first time for any indication or under any brand, were studied under the contexts of indications, mechanism of action, and side effects.
Arjun Swaminathan +2 more
doaj +1 more source
Evidence and Extrapolation: Mechanisms for Regulating Off-Label Uses of Drugs and Devices [PDF]
, 2014 A recurring, foundational issue for evidence-based regulation is deciding whether to extend governmental approval from an existing use with sufficient current evidence of safety and efficacy to a novel use for which such evidence is currently lacking ...
Abbott, Ryan, Ayres, Ian
core +3 more sources
npj Digital Medicine, 2020 At the beginning of the artificial intelligence (AI)/machine learning (ML) era, the expectations are high, and experts foresee that AI/ML shows potential for diagnosing, managing and treating a wide variety of medical conditions.
S. Benjamens +2 more
semanticscholar +1 more source
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Biomedicines, 2021 The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months. Before this SOC was established, glioblastoma (
Jacob P. Fisher, D. C. Adamson
semanticscholar +1 more source
Identification of New Drug Candidates Against \u3cem\u3eBorrelia burgdorferi\u3c/em\u3e Using High-Throughput Screening [PDF]
, 2016 Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that .300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of
Babar, Mustafeez Mujtaba +9 more
core +3 more sources
FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC.
Clinical Cancer Research, 2021 On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras, Amgen) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma proto-oncogene (KRAS) G12C ...
Erica C Nakajima +15 more
semanticscholar +1 more source